DFX Intelligence

Data Factory

A Disruptive Approach to Precision Therapies

Armatus Bio is raising expectations for FSHD with precision gene therapy.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:1515221b-bc8f-4a3b-90a9-4c4926e02146

Data as of Sep 17, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 21, 2026, 4:04 AM UTC and rebuilt at most every 15 minutes.

Relationships: 1
Dated events: 0
On other graphs: 1
Observed: Sep 12, 2026 to Sep 17, 2026
5 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

A Disruptive Approach to Precision Therapies

Portfolio company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Rounds: 0
Investors: 1
People: 0
Website: armatusbio.com

Investors

Investor	Class	Fund	Partner	Role	Attribution
Cincytech, LLC	Institutional VC	n/a	n/a	unknown	Unknown

Relationships

Invested in (1)

← Cincytech, LLCFirmPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site

Dated events

No dated event names this entity yet.

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:1515221b-bc8f-4a3b-90a9-4c4926e02146
First observed: Sep 12, 2026
Last observed: Sep 17, 2026 3 days ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.